Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes.

Zhang Y, Thamer M, Kaufman JS, Cotter DJ, Hernán MA.

Kidney Int. 2011 Sep;80(6):663-9. doi: 10.1038/ki.2011.188. Epub 2011 Jun 22.

2.

The impact of hyporesponsiveness to erythropoietin-stimulating agents on time-dependent mortality risk among CKD stage 5D patients: a single-center cohort study.

Ishigami J, Onishi T, Shikuma S, Akita W, Mori Y, Asai T, Kuwahara M, Sasaki S, Tsukamoto Y.

Clin Exp Nephrol. 2013 Feb;17(1):106-14. doi: 10.1007/s10157-012-0659-6. Epub 2012 Jul 3.

PMID:
22752396
3.

Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States.

Zhang Y, Thamer M, Cotter D, Kaufman J, Hernán MA.

Clin J Am Soc Nephrol. 2009 Mar;4(3):638-44. doi: 10.2215/CJN.05071008. Epub 2009 Mar 4.

4.

Comparative effectiveness of two anemia management strategies for complex elderly dialysis patients.

Zhang Y, Thamer M, Kaufman J, Cotter D, Hernán MA.

Med Care. 2014 Mar;52 Suppl 3:S132-9. doi: 10.1097/MLR.0b013e3182a53ca8.

5.

Is there a deleterious effect of erythropoietin in end-stage renal disease?

Singh AK.

Kidney Int. 2011 Sep;80(6):569-71. doi: 10.1038/ki.2011.190.

6.

Relative safety of peginesatide and epoetin alfa.

Weinhandl ED, Gilbertson DT, Collins AJ, Foley RN.

Pharmacoepidemiol Drug Saf. 2014 Oct;23(10):1003-11. doi: 10.1002/pds.3655. Epub 2014 Jun 6.

PMID:
24905967
7.

Erythropoiesis-stimulating agent use among non-dialysis-dependent CKD patients before and after the trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) using a large US health plan database.

Thamer M, Zhang Y, Kshirsagar O, Cotter DJ, Kaufman JS.

Am J Kidney Dis. 2014 Nov;64(5):706-13. doi: 10.1053/j.ajkd.2014.05.013. Epub 2014 Jul 8.

8.

Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study.

Ogawa T, Shimizu H, Kyono A, Sato M, Yamashita T, Otsuka K, Nitta K.

Int Urol Nephrol. 2014 Jan;46(1):151-9. doi: 10.1007/s11255-013-0494-z. Epub 2013 Jun 27.

PMID:
23807369
9.

Higher doses of erythropoietin-stimulating agents and hyporesponsiveness to their effects are associated with increased mortality among prevalent hemodialysis patients.

Nishio A, Chhatkuli BP, Ma JZ, Kalantari K.

Blood Purif. 2013;36(1):29-36. doi: 10.1159/000350583. Epub 2013 May 25.

PMID:
23735569
10.

Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease.

Horowitz J, Agarwal A, Huang F, Gitlin M, Gandra SR, Cangialose CB.

J Manag Care Pharm. 2009 Nov-Dec;15(9):741-50.

11.

Association of higher erythropoiesis stimulating agent dose and mortality in children on dialysis.

Lestz RM, Fivush BA, Atkinson MA.

Pediatr Nephrol. 2014 Oct;29(10):2021-8. doi: 10.1007/s00467-014-2820-9. Epub 2014 May 3.

12.

Perihospitalization patterns of hemoglobin levels and erythropoiesis-stimulating agent doses in US hemodialysis patients, 1998-2009.

Foley RN, Solid CA, Lamb K.

Hemodial Int. 2014 Jan;18(1):24-31. doi: 10.1111/hdi.12090. Epub 2013 Oct 17.

PMID:
24131588
13.

Peginesatide in patients with anemia undergoing hemodialysis.

Fishbane S, Schiller B, Locatelli F, Covic AC, Provenzano R, Wiecek A, Levin NW, Kaplan M, Macdougall IC, Francisco C, Mayo MR, Polu KR, Duliege AM, Besarab A; EMERALD Study Groups..

N Engl J Med. 2013 Jan 24;368(4):307-19. doi: 10.1056/NEJMoa1203165.

14.

Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients.

Hahn D, Cody JD, Hodson EM.

Cochrane Database Syst Rev. 2014 May 28;(5):CD003895. doi: 10.1002/14651858.CD003895.pub3. Review.

PMID:
24872328
15.

Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan.

Fukuma S, Yamaguchi T, Hashimoto S, Nakai S, Iseki K, Tsubakihara Y, Fukuhara S.

Am J Kidney Dis. 2012 Jan;59(1):108-16. doi: 10.1053/j.ajkd.2011.07.014. Epub 2011 Sep 3.

PMID:
21890255
16.

Treatment with high dose of erythropoiesis-stimulating agents and mortality: analysis with a sequential Cox approach and a marginal structural model.

Suttorp MM, Hoekstra T, Mittelman M, Ott I, Krediet RT, Dekker FW, Putter H.

Pharmacoepidemiol Drug Saf. 2015 Oct;24(10):1068-75. doi: 10.1002/pds.3855. Epub 2015 Aug 12.

PMID:
26265483
17.

Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis.

Thamer M, Zhang Y, Kaufman J, Cotter D, Dong F, Hernán MA.

JAMA. 2007 Apr 18;297(15):1667-74.

PMID:
17440144
18.

[Effects of dose of erythropoiesis stimulating agents on cardiovascular outcomes, quality of life and costs of haemodialysis. the clinical evaluation of the DOSe of erythropoietins (C.E. DOSE) Trial].

Saglimbene V, D'Alonzo D, Ruospo M, Vecchio M, Natale P, Gargano L, Nicolucci A, Pellegrini F, Craig JC, Triolo G, Procaccini DA, Santoro A, Di Giulio S, La Rosa S, Murgo A, Di Toro Mammarella R, Sambati M, D'Ambrosio N, Greco V, Giannoccaro G, Flammini A, Boccia E, Montalto G, Pagano S, Amarù S, Fici M, Lumaga GB, Mancini E, Veronesi M, Patregnani L, Querques M, Schiavone P, Chimienti S, Palumbo R, Di Franco D, Della Volpe M, Gori E, Salomone M, Iacono A, Moscoloni M, Treglia A, Casu D, Piras AM, Di Silva A, Mandreoli M, Lopez A, Quarello F, Catizone L, Russo G, Forcellini S, Maccarone M, Catucci G, Di Paolo B, Stingone A, D'Angelo B, Guastoni C, Pasquali S, Minoretti C, Bellasi A, Boscutti G, Martone M, David S, Schito F, Urban L, Di Iorio B, Caruso F, Mazzoni A, Musacchio R, Andreoli D, Cossu M, Li Cavoli G, Cornacchiari M, Granata A, Clementi A, Giordano R, Guastoni C, Barzaghi W, Valentini M, Hegbrant J, Tognoni G, Strippoli GF.

G Ital Nefrol. 2013 Mar-Apr;30(2). pii: gin/30.2.21. Italian.

PMID:
23832463
19.

Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.

Forbes CA, Worthy G, Harker J, Kleijnen J, Kutikova L, Zelek L, Van Belle S.

Clin Ther. 2014 Apr 1;36(4):594-610. doi: 10.1016/j.clinthera.2014.02.007. Epub 2014 Mar 18. Review.

20.

2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.

Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T.

Ther Apher Dial. 2010 Jun;14(3):240-75. doi: 10.1111/j.1744-9987.2010.00836.x.

PMID:
20609178

Supplemental Content

Support Center